{"groups":[{"description":"Participants received enzalutamide 160 mg orally once daily until confirmed radiographic disease progression, skeletal-related event or the initiation of a new antineoplastic therapy.","id":"FG000","title":"Enzalutamide"},{"description":"Participants received bicalutamide 50 mg orally once daily until confirmed radiographic disease progression, skeletal-related event or the initiation of a new antineoplastic therapy.","id":"FG001","title":"Bicalutamide"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"7"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"75"},{"groupId":"FG001","numSubjects":"103"}],"type":"Progressive Disease"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Protocol Violation"},{"reasons":[{"groupId":"FG000","numSubjects":"25"},{"groupId":"FG001","numSubjects":"26"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"29"},{"groupId":"FG001","numSubjects":"42"}],"type":"Miscellaneous Reason"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"}],"type":"Randomized but never received study drug"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"184"},{"groupId":"FG001","numSubjects":"191"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"183"},{"groupId":"FG001","numSubjects":"189"}],"type":"Received Treatment"},{"achievements":[{"comment":"Indicates participants were still receiving treatment at the data cut-off date of 19 October 2014.","groupId":"FG000","numSubjects":"42"},{"comment":"Indicates participants were still receiving treatment at the data cut-off date of 19 October 2014.","groupId":"FG001","numSubjects":"9"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"142"},{"groupId":"FG001","numSubjects":"182"}],"type":"NOT COMPLETED"}],"title":"Double-blind Period"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"18"},{"groupId":"FG001","numSubjects":"3"}],"type":"Progressive disease"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"0"}],"type":"Miscellaneous Reason"},{"reasons":[{"groupId":"FG000","numSubjects":"17"},{"groupId":"FG001","numSubjects":"5"}],"type":"Transitioned to 9785-CL-0123 NCT02960022"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"42"},{"groupId":"FG001","numSubjects":"9"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"42"},{"groupId":"FG001","numSubjects":"9"}],"type":"Received Treatment"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"42"},{"groupId":"FG001","numSubjects":"9"}],"type":"NOT COMPLETED"}],"title":"Open-label Period (All Enzalutamide)"}],"preAssignmentDetails":"Participants were stratified by whether bilateral orchiectomy or receipt of luteinizing hormone-releasing hormone (LHRH) agonist/antagonist therapy started before or after the diagnosis of metastases and by site.","recruitmentDetails":"Men with metastatic castration-resistant prostate cancer (mCRPC) were enrolled at 84 sites in a total of 8 countries."}